All News

Quality of life also appears to be maintained with elacestrant in estrogen receptor–positive or HER2-negative ESR1-mutated breast cancer in the phase 3 EMERALD trial.

The phase 3 NRG GY018 trial added immunotherapy to chemotherapy in patients with recurrent endometrial cancer, regardless of mismatch repair deficient or proficient disease status, according to Ramez N. Eskander, MD.

Safety findings in the phase 1b DESTINY-Breast08 are comparable with prior reports of trastuzumab deruxtecan and endocrine therapy in HER2-low hormone receptor–positive metastatic breast cancer.

Treatment with visugromab plus nivolumab in patients with relapsed/refractory solid tumors in the phase 2a GDFATHER-2 trial appears to exhibit safety and tolerability.

Data from the phase 3 TROPION-Breast01 trial support datopotamab deruxtecan as a potential treatment option for patients with endocrine-resistant, hormone receptor–positive, metastatic breast cancer, says Aditya Bardia, MD, MPH.

Trastuzumab deruxtecan produces the longest time to next treatment in patients with HER2-positive or stable HER2-low advanced breast cancer in the RELIEVE study.

The DEBBRAH trial met its primary endpoint of overall survival in a cohort of patients with HER2-positive or HER2-low advanced breast cancer and leptomeningeal carcinomatosis with positive cerebrospinal fluid cytology.

Heather A. Parsons, MD, MPH, says she is excited about HER2 as a biomarker and investigating the biology of metastatic breast cancer with a minimally invasive liquid biopsy platform.

Data highlight the importance of genomic testing to help optimize treatment and reduce disparities for Black patients with hormone receptor–positive HER2-negative breast cancer, according to Sonya Reid, MD, MPH.

Trastuzumab emtansine plus tucatinib has promising clinical activity and a manageable safety profile in HER2-positive metastatic breast cancer, says Sara A. Hurvitz, MD.

Data from the phase 2 KEYLYNK-009 study indicate a lower rate of treatment-related adverse effects with pembrolizumab plus olaparib compared with pembrolizumab plus chemotherapy in those with triple-negative breast cancer.

The safety profile of nivolumab plus ipilimumab in the phase 3 CheckMate 8HW trial is comparable with prior reports of each individual agent.

The pembrolizumab-based regimen in the phase 3 KEYNOTE-756 trial produces a larger pathologic complete response benefit in patients with node-positive disease and higher PD-L1 expression, according to Joyce O’Shaughnessy, MD.

Preclinical research supports the rationale of combining a BDC-1001 surrogate with pertuzumab to target HER2-expressing tumors.

Compared with surgery and radiation, focal therapy improves quality of life as well as decreases financial toxicity for patients with prostate cancer.

A future planned analysis of the monarchE trial may further define how circulating tumor DNA dynamics can help identify patients with hormone receptor–positive HER2-negative breast cancer who are at high risk of recurrence.

Treatment with iparomlimab appears to be tolerable in patients with unresectable or metastatic mismatch repair deficient or microsatellite instability–high solid tumors in a phase 2 trial.

Combining capivasertib with fulvestrant improves time to deterioration compared with placebo plus fulvestrant among patients with hormone receptor–positive, HER2-negative breast cancer in the CAPItello-291 trial.

Partial breast irradiation is associated with lower financial toxicities and fewer AEs in patients with early-stage breast cancer compared with whole breast irradiation.

Future-looking models see a large decrease in the cost of running sentinel lymph node assessments when artificial intelligence is used.

Combining ribociclib with endocrine therapy appears to be effective and tolerable for those with hormone receptor–positive HER2-negative advanced breast cancer, including elderly patients.

Median overall survival appears to be higher in patients who were previously treated with relapsed/refractory mantle cell lymphoma and who receive brexucabtagene autoleucel compared with standard therapy.

Despite the addition of a TIGIT inhibitor to a checkpoint inhibitor resulting in high levels of safety, there is no future for that combination alone, according to Ritu Salani, MD.

The FDA has set a Prescription Drug User Fee Act date of April 5, 2024 for nivolumab plus chemotherapy in unresectable or metastatic urothelial carcinoma.

Implementing exercise programs into standard oncology care may help improve quality of life for patients with ovarian cancer.

Investigators will assess LP-284 as a treatment for those with B-cell non-Hodgkin lymphoma in a phase 1 trial.

The addition of a TIGIT inhibitor to a checkpoint inhibitor showed numerical improvement but did not show statistical significance in patients with recurrent cervical cancer, according to Ritu Salani, MD.

Surgery after neoadjuvant immune checkpoint inhibitor therapy for renal cell carcinoma is safe even in challenging surgical cases, according to Jason Scovell, MD.

Treatment with blinatumomab or inotuzumab ozogamicin particularly confers higher total costs for patients with relapsed/refractory B-cell acute lymphoblastic leukemia.

The safety profile of venetoclax following allogeneic hematopoietic stem cell transplantation in patients with chronic lymphocytic leukemia appears to be comparable with other reports in clinical trials.